All In Biotech

Drug Trial Radar · NCT05717348

A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours

An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase 1 Clinical Study of ES014 Administered in Patients Locally Advanced or Metastatic Solid Tumours

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Feb 24, 2023

Primary completion

Feb 28, 2027

Study completion Feb 28, 2027

Sponsor

Sponsor type
Industry
First posted
Feb 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this first-in-human, open-label, multicenter, non-randomized study designed to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD), optimal biological dose (OBD), and recommended phase 2 dose (RP2D) of ES014 by evaluating the safety, tolerability, PK, pharmacodynamics, and preliminary clinical activity of ES014 administered intravenously to subjects with advanced solid tumors.

Conditions

  • Solid Tumor
  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor

Interventions

  • ES014Drug

    ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The frequency and severity of adverse events of ES014Time frame: 1-3 years
  2. Dose Limiting Toxicity of ES014Time frame: 1-3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Chest Hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.